RT Book, Section
A1 Wang, Sunny
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1184389489
T1 Bronchogenic Carcinoma
T2 Current Medical Diagnosis & Treatment 2022
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264269389
LK accessmedicine.mhmedical.com/content.aspx?aid=1184389489
RD 2024/04/19
AB Key  Clinical  Updates  in  Bronchogenic  CarcinomaROS1-rearranged  lung  cancers  respond  to  crizotinib  (ALK,  cMET,  and  ROS1  tyrosine  kinase  inhibitor)  and  entrectinib  (multikinase  inhibitor,  including  ROS-1)  with  response  rates  over  70%.For  patients  whose  NSCLC  reveals  NTRK  1/2/3  gene  fusion,  treatment  with  larotrectinib  (TRKA/B/C  inhibitor)  or  entrectinib  (multikinase  inhibitor,  including  TRKA/B/C)  is  recommended.Selpercatinib  and  pralsetinib  (RET  inhibitors)  are  recommended  first-line  treatments  for  RET  fusion-positive  NSCLC.